TWM568137U - Encapsulated particle coated with lion's mane mushroom powder - Google Patents

Encapsulated particle coated with lion's mane mushroom powder Download PDF

Info

Publication number
TWM568137U
TWM568137U TW107202552U TW107202552U TWM568137U TW M568137 U TWM568137 U TW M568137U TW 107202552 U TW107202552 U TW 107202552U TW 107202552 U TW107202552 U TW 107202552U TW M568137 U TWM568137 U TW M568137U
Authority
TW
Taiwan
Prior art keywords
day
hericium erinaceus
powder
once
coated
Prior art date
Application number
TW107202552U
Other languages
Chinese (zh)
Inventor
蔣文欽
林育民
郭俊宏
林智庸
Original Assignee
傑安生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 傑安生技股份有限公司 filed Critical 傑安生技股份有限公司
Priority to TW107202552U priority Critical patent/TWM568137U/en
Publication of TWM568137U publication Critical patent/TWM568137U/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

一種包覆猴頭菇粉末的包埋顆粒,包括多個猴頭菇粉末、一膠狀物質層及一食用殼層。猴頭菇粉末其直徑範圍為10微米至12微米。膠狀物質層包覆該猴頭菇粉末。食用殼層包覆該膠狀物質層。 An embedded granule coated with a powder of Hericium erinaceus, comprising a plurality of Hericium erinaceus powder, a gelatinous substance layer and an edible shell layer. The Hericium erinaceus powder has a diameter ranging from 10 microns to 12 microns. The gelatinous substance layer coats the Hericium erinaceus powder. The edible shell layer coats the layer of the gelatinous substance.

Description

包覆猴頭菇粉末的包埋顆粒 Encapsulated particles coated with Hericium erinaceus powder

本創作有關健康食品領域,更具體地,有關一種包覆猴頭菇粉末的包埋顆粒。 This creation relates to the field of health foods, and more particularly to an embedded particle coated with a powder of Hericium erinaceus.

全球人口老化,神經退化性疾病日漸受到重視,其中,巴金森氏症(Parkinson’s disease)的盛行率(prevalence)在台灣正以每年7.9%的年增率穩定上升,臨床治療以給予病人補充多巴胺為主(左旋多巴/Levodopa)。現行療法治標不治本,儘管有效,但長期用藥2-5年後,藥效會逐漸減弱(Wearing-off)而最終失去療效。站在預防醫學的角度,有別於藥物治療疾病所講求的藥效,聚焦神經保護概念,開發經過製程嚴格管控、功效成分分析確效、科學化功效性與安全性認證的健康食品,除可行預防勝於治療之實,促進健康與延緩老化等功能,也可緩解因人口高齡化、慢性病患者增加而導致的國家醫療支出與社會福利負擔。 The global population is aging, and neurodegenerative diseases are receiving increasing attention. Among them, the prevalence of Parkinson's disease is rising steadily in Taiwan at an annual rate of 7.9% per year. Clinical treatment is to supplement patients with dopamine. Lord (levodopa / Levodopa). The current treatment is not a cure, although effective, but after 2-5 years of long-term medication, the efficacy will gradually weaken (Wearing-off) and eventually lose efficacy. From the perspective of preventive medicine, it is different from the efficacy of drug treatment for diseases, focusing on the concept of neuroprotection, and developing healthy foods that are strictly controlled by the process, effective in the analysis of functional components, scientifically validated and safely certified, except feasible. Prevention is better than cure, promoting health and delaying aging. It can also alleviate the burden of national medical expenditure and social welfare caused by the aging population and the increase of chronic diseases.

猴頭菇(Hericium erinaceus)隸屬於猴頭菇科(Hericiaceae),猴頭菌屬之蕈類,在中國其用於治療胃炎已有千年之久。根據《中國藥用真菌》記載,其味甘、性平、能利五臟、助消化、滋補,對消化不良、神經衰退、十二指腸潰瘍及胃潰瘍有良好的功效。現代科學文獻也應證其功效,猴頭菇多醣體萃取液可調控ICRs小鼠的免疫活性、並且對於轉移性肺癌有顯著的抗癌作用。在免疫方面,其多醣體萃取液能增強及調控T cell和macrophage的能力,例如增加NO生成和增加cytokinses(IL-1 β和TNF-β)表現,此作用可能是猴頭菇多醣體萃取液能抗癌的原因之一。此外,已有數篇文獻驗證其在神經保護方面的作用,例如猴頭 菇乙醇萃取液能透過JNK pathway調控並促進NGF的mRNA表現,此研究有利於失智與認知功能障礙疾病的治療,其研究結果顯示在amyloid β(25-35)peptides誘導產生短期空間與視覺辨識記憶受損的ICR小鼠上,給予猴頭菇粉末後能預防其神經受到損害。在日本的臨床試驗結果指出,50歲到80歲輕度認知障礙受試者口服給予猴頭菇粉末能改善對認知功能量表評分的分數,其結果顯示猴頭菇對於延緩腦部功能性退化之功效,且具有進一步研究開發之價值。 Hericium erinaceus belongs to the family Herricaceae, a genus of the genus Hericium, which has been used in China for the treatment of gastritis for thousands of years. According to the "Chinese Medicinal Fungi", it is sweet, flat, can benefit the five internal organs, help digestion, nourish, and has good effects on indigestion, neurodegenerative, duodenal ulcer and gastric ulcer. The modern scientific literature should also prove its efficacy. The polysaccharide extract of Hericium erinaceus can regulate the immune activity of ICRs mice and has a significant anticancer effect on metastatic lung cancer. In terms of immunity, its polysaccharide extract can enhance and regulate T cell and macrophage, such as increasing NO production and increasing cytokinses (IL-1 β and TNF-β). This effect may be the polysaccharide extract of Hericium erinaceus. One of the reasons for cancer resistance. In addition, several papers have been published to verify their role in neuroprotection, such as the monkey head. The mushroom ethanol extract can regulate and promote the mRNA expression of NGF through JNK pathway. This study is beneficial to the treatment of dementia and cognitive dysfunction diseases. The results show that short-term spatial and visual identification is induced by amyloid β(25-35)peptides. In ICR mice with impaired memory, the monkey mushroom powder can be used to prevent damage to the nerves. The results of clinical trials in Japan indicate that oral administration of Hericium erinaceus powder to subjects with mild cognitive impairment between the ages of 50 and 80 can improve the score on the cognitive function scale, and the results show that Hericium erinaceus delays functional degradation of the brain. The efficacy, and the value of further research and development.

但是,藥材的食用多是採用燉煮或研磨,該方法的成分有效率僅有10~30%。目前還有超細製劑的技術,雖可提高有效利用率,但由於超細製劑細胞破壁率增加,存在破壁製劑表面積增大,形狀不規則,流動性、分散性差,易於吸濕,穩定性差等固有特點,應用上仍有改善的需求。又經超細製劑技術壓製的粉末,對於酸鹼度非常敏感,若粉末直接進入人體可能受到胃酸或膽汁的殺菌作用影響,在被人體吸收前便被破壞,因人體無法吸收導致粉末的效果大打折扣,且存放也不易。因此,如何克服上述問題便是本領域具通常知識者值得去思量的。 However, the consumption of medicinal materials is mostly stewed or ground. The efficiency of the method is only 10~30%. At present, there is also a technology of ultra-fine preparation, although the effective utilization rate can be improved, but due to the increased cell wall breaking rate of the ultra-fine preparation, the surface area of the broken-wall preparation increases, the shape is irregular, the fluidity and the dispersibility are poor, and it is easy to absorb moisture and stabilize. Inherent characteristics such as poor performance, there is still an improved demand in application. The powder which is pressed by the ultra-fine preparation technology is very sensitive to the pH. If the powder directly enters the human body, it may be affected by the bactericidal action of gastric acid or bile, and it will be destroyed before being absorbed by the human body, and the effect of the powder is greatly reduced because the human body cannot absorb it. And it is not easy to store. Therefore, how to overcome the above problems is worthy of consideration in the field of ordinary knowledge.

本創作提供一種包覆猴頭菇粉末的包埋顆粒,猴頭菇粉末受到膠狀物質層一食用殼層的包覆,即可避免胃酸與膽汁的影響,通過胃而到腸道,有利於人體吸收。 The present invention provides an embedded granule coated with the powder of Hericium erinaceus. The powder of Hericium erinaceus is coated with a layer of a gelatinous substance to avoid the influence of gastric acid and bile, and is beneficial to the intestine through the stomach. The body absorbs.

本創作提供一種包覆猴頭菇粉末的包埋顆粒,包括多個猴頭菇粉末及一膠狀物質層。猴頭菇粉末其直徑範圍為10微米至12微米。膠狀物質層包覆該猴頭菇粉末。食用殼層包覆該膠狀物質層。 The present invention provides an embedded granule coated with a powder of Hericium erinaceus, comprising a plurality of Hericium erinaceus powder and a layer of a gelatinous substance. The Hericium erinaceus powder has a diameter ranging from 10 microns to 12 microns. The gelatinous substance layer coats the Hericium erinaceus powder. The edible shell layer coats the layer of the gelatinous substance.

上述的包覆猴頭菇粉末的包埋顆粒,其中,還包括一食用殼層,是包覆該膠狀物質層。 The above-mentioned coated particles of the coated Hericium erinaceus powder further comprise an edible shell layer covering the gelatinous substance layer.

上述的包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠紋狀體組織內神經傳遞物質多巴胺含量為226.80±66.03ng/g。 The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the dopamine content of the neurotransmitter in the striatum of the mouse was 226.80±66.03 ng/g.

上述的包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠肝臟的脂質過氧化物丙二醛含量為772.86±225.23μM。 The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the lipid peroxide malondialdehyde content of the mouse liver was 772.86±225.23 μM.

上述的包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠肝臟的羰基含量為385.05±235.15nmol/mg。 The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the carbonyl content of the mouse liver was 385.05±235.15 nmol/mg.

上述的包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠8-oxodG含量為0.73±0.18ng/mL。 The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, and the mouse 8-oxodG content was 0.73±0.18 ng/mL.

上述的包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠血液中的超氧化物歧化酵素含量為89.68±2.71U/ml。 The above-mentioned coated particles of the Hericium erinaceus powder, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a dose of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl-4-phenyl-1. 2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the superoxide dismutase content in the blood of the mice was 89.68±2.71 U/ml.

100‧‧‧包覆猴頭菇粉末的包埋顆粒 100‧‧‧Encapsulated particles coated with Hericium erinaceus powder

110‧‧‧猴頭菇粉末 110‧‧‧Herbal mushroom powder

120‧‧‧膠狀物質層 120‧‧‧Colloidal layer

130‧‧‧食用殼層 130‧‧‧ edible shell

圖1顯示給藥組紋狀體組織內神經傳遞物質多巴胺的含量分析。 Figure 1 shows the analysis of the content of the neurotransmitter dopamine in the striatal tissue of the administration group.

圖2顯示給藥組肝臟組織MDA的含量分析。 Figure 2 shows the analysis of the content of MDA in the liver tissue of the administration group.

圖3顯示給藥組肝臟組織中羰基的含量分析。 Figure 3 shows the analysis of the content of carbonyl groups in the liver tissue of the administration group.

圖4顯示給藥組肝臟組織中8-oxodG含量分析。 Figure 4 shows the analysis of 8-oxodG content in liver tissue of the administration group.

圖5顯示給藥組血液中SOD酵素活性分析。 Figure 5 shows the analysis of SOD enzyme activity in the blood of the administration group.

圖6顯示給藥組血液中Catalase酵素活性分析。 Figure 6 shows the analysis of Catalase enzyme activity in the blood of the administration group.

圖7顯示給藥組血液中G6PDH酵素活性分析。 Figure 7 shows the analysis of G6PDH enzyme activity in the blood of the administration group.

圖8顯示給藥組血液中GPx酵素活性分析。 Figure 8 shows the analysis of GPx enzyme activity in the blood of the administration group.

圖9顯示給藥組血液中GRd酵素活性分析。 Figure 9 shows the analysis of GRd enzyme activity in the blood of the administration group.

圖10所繪示為本創作的包覆猴頭菇粉末的包埋顆粒。 Figure 10 depicts the embedded particles of the coated Hericium erinaceus powder of the present invention.

請參閱圖10,圖10所繪示為本創作的包覆猴頭菇粉末的包埋顆粒。包覆猴頭菇粉末的包埋顆粒包括了多個猴頭菇粉末110、一膠狀物質層120及一食用殼體層130。膠狀物質層120是包覆猴頭菇粉末110,食用殼層130則是包覆膠狀物質層120外。膠狀物質層120與食用殼層130呈現一個多層同心圓結構,包覆猴頭菇粉末110,使其成為一個球體,方便使用者食用。並且猴頭菇粉末110受膠狀物質層120與食用殼層130包覆,即可避免胃酸與膽汁的影響,通過胃而到腸道,有利於人體吸收。而關於猴頭菇粉末110,其說明如下: Please refer to FIG. 10 , which illustrates the embedded particles of the coated Hericium erinaceus powder of the present invention. The embedded particles coated with the Hericium erinaceus powder include a plurality of Hericium erinaceus powders 110, a gelatinous substance layer 120, and an edible casing layer 130. The gelatinous substance layer 120 is coated with the Hericium erinaceus powder 110, and the edible shell layer 130 is covered with the gelatinous substance layer 120. The gelatinous substance layer 120 and the edible shell layer 130 exhibit a multi-layered concentric structure, encapsulating the Hericium erinaceus powder 110, making it a sphere for convenient consumption by the user. And the Hericium erinaceus powder 110 is covered by the gelatinous substance layer 120 and the edible shell layer 130, thereby avoiding the influence of gastric acid and bile, and passing through the stomach to the intestinal tract, which is beneficial to the human body to absorb. Regarding the Hericium erinaceus powder 110, the description is as follows:

本創作係以誘導型老化模式-MPTP誘導巴金森氏症動物模式來評估不同粒徑的猴頭菇粉末對於延緩衰老之功效影響。判讀腦部衰老依據主要係採用最易衰老的腦組織紋狀體進行多巴胺含量的分析;血液樣本用於抗氧化生化指標測定,包含超氧化物歧化酵素(superoxide dismutase,SOD)活性之測定、葡萄糖六磷酸去氫酵素(glucose-6-phosphate dehydrogenase,G6PD)活性測定、過氧化氫酵素(catalase)活性測定、麩胱甘肽過氧化酵素(glutathione peroxidase,GPx)活性之測定和麩胱甘肽還原酵素(glutathione reductase,GRd)活性之測定。另外,肝臟組織亦 為易衰老組織,分別測定粒線體DNA之8-羥基-2-去氧鳥嘌呤核甘(8-oxodG)、氧化修飾後蛋白羰基功能基含量測定和脂質氧化丙二醛TBARS定量分析。 This creation evaluates the effect of different sizes of Hericium erinaceus powder on anti-aging effects by inducing aging mode-MPTP-induced animal model of Parkinson's disease. Interpretation of brain aging is based on the analysis of dopamine content in the most aging brain tissue striatum; blood samples are used for the determination of antioxidant biochemical indicators, including the determination of superoxide dismutase (SOD) activity, glucose Determination of glucose-6-phosphate dehydrogenase (G6PD) activity, determination of catalase activity, determination of glutathione peroxidase (GPx) activity and glutathione reduction Determination of the activity of glutathione reductase (GRd). In addition, liver tissue is also For the aging tissue, the 8-hydroxy-2-deoxyguanosine nucleus (8-oxodG) of mitochondrial DNA, the oxidatively modified protein carbonyl functional group content and the lipid oxidized malondialdehyde TBARS quantitative analysis were determined.

實驗係以六週齡C57BL/6Narl(n=75)雄性小鼠進行,其購自台灣國家動物中心。飼養在國立陽明大學實驗動物中心,環境溫度24±1℃與12:12小時光暗週期。 The experiment was carried out in 6-week old C57BL/6 Narl (n=75) male mice purchased from the National Animal Center of Taiwan. It is housed in the Experimental Animal Center of the National Yangming University, with an ambient temperature of 24 ± 1 ° C and a 12: 12 hour light and dark cycle.

給藥條件分為5組,健康空白組:不給予任何藥物,給予等體積的蒸餾水,口服一天一次,30days.(n=15)、疾病空白組:MPTP 20mg/kg,腹腔內注射一天一次,5days+蒸餾水,口服一天一次,30days.(n=15)、JWH001組:MPTP 20mg/kg,腹腔內注射一天一次,5days+JWH001 powder,1g/kg,口服一天一次,30days.(n=15)、中粉組:MPTP 20mg/kg,腹腔內注射一天一次,5days+中粉,1g/kg,口服一天一次,30days.(n=15)、及粗粉組:MPTP 20mg/kg,腹腔內注射一天一次,5days+粗粉,1g/kg,口服一天一次,30days.(n=15)。 The administration conditions were divided into 5 groups, healthy blank group: no drug was given, equal volume of distilled water was given, once a day, 30 days. (n=15), disease blank group: MPTP 20 mg/kg, intraperitoneal injection once a day, 5days+ distilled water, once a day, 30days. (n=15), JWH001 group: MPTP 20mg/kg, intraperitoneal injection once a day, 5days+JWH001 powder, 1g/kg, once a day, 30days. (n=15), Medium powder group: MPTP 20mg/kg, intraperitoneal injection once a day, 5days+ medium powder, 1g/kg, once a day, 30days. (n=15), and coarse powder group: MPTP 20mg/kg, intraperitoneal injection once a day , 5days + coarse powder, 1g / kg, oral once a day, 30days. (n = 15).

以上JWH001組為本創作之一實施例,粒徑D50範圍為10微米-12微米;中粉組粒徑D50範圍為16微米-20微米;及粗粉組粒徑D50範圍為85微米-100微米。一實施例中,本創作將市售猴頭菇粉末粒徑D50範圍為100微米的一般粉(菌株來源:BCRC Number:36470),經氣流式超微粉碎機(Spiral Jet Mill,OM2 Micronizer,Sturtevant,Int.,Hanover,MA USA),在入料速度30-40g/min,研磨壓力90-100 PSIG與入料壓力50-60 PSIG的操作條件下,進行微粉化,達到粒徑D50為10μm。 The above JWH001 group is one embodiment of the creation, the particle diameter D50 ranges from 10 micrometers to 12 micrometers; the medium powder group has a particle diameter D50 ranging from 16 micrometers to 20 micrometers; and the coarse powder group has a particle diameter D50 ranging from 85 micrometers to 100 micrometers. . In one embodiment, the creation of a commercially available product of the Hericium erinaceus powder having a particle size D50 of 100 micrometers (strain source: BCRC Number: 36470), via a gas flow superfine pulverizer (Spiral Jet Mill, OM2 Micronizer, Sturtevant) , Int., Hanover, MA USA), under the operating conditions of a feed rate of 30-40 g/min, a grinding pressure of 90-100 PSIG and a feed pressure of 50-60 PSIG, micronization was carried out to a particle size D50 of 10 μm.

對於以上5組,實驗設計如下,(1)健康對照組/給予等體積生理食鹽水:以生理食鹽水腹腔注射五天,同步管灌餵食方式給予等體積蒸餾水三十天,第三十一天做小鼠腦部解剖,手術器具將腦部與肝臟組織組織取下,並分離紋狀體至於離心管內,所有採集的樣品於分析之前冰存於-20℃冰箱。以心臟採血方式採血1mL。(2)疾病對照組/MPTP 20mg/kg,ip+給予等體積蒸餾水:給予MPTP 20mg/kg腹腔注射五天與同步以管灌餵食方式給予等體積蒸餾水三十天,第三十 一天做小鼠腦部解剖,手術器具將腦部與肝臟組織組織取下,並分離紋狀體至於離心管內,所有採集的樣品於分析之前冰存於-20℃冰箱。以心臟採血方式採血1mL。(3)實驗組/MPTP 20mg/kg,ip+給予猴頭菇粉末1g/kg,po,QD:給予MPTP 20mg/kg腹腔注射與同步以管灌餵食方式給予猴頭菇粉末1g/kg五天,第六天起,維持給予猴頭菇粉末1g/kg直至三十天,第三十一天做小鼠腦部解剖,手術器具將腦部與肝臟組織組織取下,並分離紋狀體至於離心管內,所有採集的樣品於分析之前冰存於-20℃冰箱。以心臟採血方式採血1mL。(4)實驗組/MPTP 20mg/kg,ip+給予中粉1g/kg,po,QD:給予MPTP 20mg/kg腹腔注射與同步以管灌餵食方式給予猴頭菇粉末1g/kg五天,第六天起,維持給予猴頭菇粉末1g/kg直至三十天,第三十一天做小鼠腦部解剖,手術器具將腦部與肝臟組織組織取下,並分離紋狀體至於離心管內,所有採集的樣品於分析之前冰存於-20℃冰箱。以心臟採血方式採血1mL。(5)實驗組/MPTP 20mg/kg,ip+給予粗粉1g/kg,po,QD:給予MPTP 20mg/kg腹腔注射與同步以管灌餵食方式給予猴頭菇粉末1g/kg五天,第六天起,維持給予猴頭菇粉末1g/kg直至三十天,第三十一天做小鼠腦部解剖,手術器具將腦部與肝臟組織組織取下,並分離紋狀體至於離心管內,所有採集的樣品於分析之前冰存於-20℃冰箱。以心臟採血方式採血1mL。 For the above 5 groups, the experimental design is as follows: (1) healthy control group/administer an equal volume of physiological saline: intraperitoneal injection for five days in physiological saline, and equal volume of distilled water for 30 days in the same way. The mouse brain was dissected, the surgical instrument removed the brain and liver tissue, and the striatum was separated into the centrifuge tube. All the collected samples were stored in a refrigerator at -20 °C before analysis. 1 mL of blood was collected by cardiac blood sampling. (2) disease control group / MPTP 20mg / kg, ip + to give an equal volume of distilled water: give MPTP 20mg / kg intraperitoneal injection for five days and synchronous pipe irrigation to give an equal volume of distilled water for thirty days, the thirtieth One day, the mouse brain was dissected, the surgical instrument removed the brain and liver tissue, and the striatum was separated into the centrifuge tube. All the collected samples were stored in a refrigerator at -20 °C before analysis. 1 mL of blood was collected by cardiac blood sampling. (3) Experimental group/MPTP 20mg/kg, ip+ to be given 1g/kg of Hericium erinaceus powder, po, QD: Give MPTP 20mg/kg intraperitoneally and synchronously to give the Hericium erinaceus powder 1g/kg for 5 days. From the sixth day, the rabbit mushroom powder was maintained for 1g/kg until 30 days. On the 31st day, the mouse brain was dissected. The surgical instrument removed the brain and liver tissue and separated the striatum for centrifugation. Inside the tube, all samples collected were stored in a -20 ° C freezer prior to analysis. 1 mL of blood was collected by cardiac blood sampling. (4) Experimental group/MPTP 20mg/kg, ip+ administered medium powder 1g/kg, po, QD: Give MPTP 20mg/kg intraperitoneal injection and synchronous tube feeding method to give the monkey mushroom powder 1g/kg for five days, sixth From day on, I will continue to give 1g/kg of Hericium erinaceus powder until 30 days. On the 31st day, the mouse brain will be dissected. The surgical instrument will remove the brain and liver tissue and separate the striatum into the centrifuge tube. All collected samples were stored in a refrigerator at -20 ° C before analysis. 1 mL of blood was collected by cardiac blood sampling. (5) experimental group / MPTP 20mg / kg, ip + to give crude powder 1g / kg, po, QD: give MPTP 20mg / kg intraperitoneal injection and synchronous tube feeding method to give the monkey mushroom powder 1g / kg for five days, the sixth From day on, I will continue to give 1g/kg of Hericium erinaceus powder until 30 days. On the 31st day, the mouse brain will be dissected. The surgical instrument will remove the brain and liver tissue and separate the striatum into the centrifuge tube. All collected samples were stored in a refrigerator at -20 ° C before analysis. 1 mL of blood was collected by cardiac blood sampling.

MPTP配製在生理食鹽水中濃度為4mg/ml,按照體重給藥最終劑量20mg/kg。 The MPTP was prepared at a concentration of 4 mg/ml in physiological saline, and the final dose was 20 mg/kg according to the body weight.

(腦部組織老化之生物活性指標測定) (Measurement of biological activity index of brain tissue aging)

關於腦部紋狀體多巴胺含量測定,首先進行腦部紋狀體取樣:於第三十天給完藥後24小時,給予小鼠鼠腹腔注射100mg/kg尿烷麻醉,以心臟採血法採集血液樣本,放入離心管並放置於冰上,存放於-80℃。而後,剪開腦殼將腦取出,屍體以可燃式環保塑膠袋裝妥,送陽明大學動物中心焚化處理。將紋狀體組織從腦部分離出,浸泡於保存液中,分析前存放於-80℃。接著,製備分析樣 品:組織存放於保存液(Stock solution:0.1M HClO4,0.1mM EDTA,0.1mM Na2S2O5)均質過後,離心取上清液(13000rpm,10min),利用電化學分析紋狀體組織內神經傳導物質多巴胺變化。接著,分別分析多巴胺(DA),標準品係購自Sigma Aldrich。分析條件如下,管柱為Suhshell C18,100×4.6mm,2.6μm;移動相(1L,pH 3.74):0.74mM鈉-1-辛烷氨基磺酸鹽(Sodium-1-Octanesulfaoate,SOS)、100mM磷酸鈉鹽(Phosphate sodium salt)、0.027mM EDTA 2M氯化鉀和60mL甲醇;偵測器:Decade II,使用玻璃碳電極於施加電位為650mV vs.Ag/AgCl的數位電化學安培計量偵測器;流率:500μL/min;範圍:5nA;注射體積:15μL。 For the determination of dopamine content in the striatum of the brain, the striatum sampling of the brain was first performed: 24 hours after the completion of the drug on the 30th day, the mice were intraperitoneally injected with 100 mg/kg urethane anesthesia, and blood was collected by cardiac blood sampling. The sample was placed in a centrifuge tube and placed on ice and stored at -80 °C. Then, the brain was cut open and the brain was taken out. The body was packed in a flammable green plastic bag and sent to the Yangming University Animal Center for incineration. The striatum was separated from the brain, immersed in the preservation solution, and stored at -80 °C before analysis. Next, prepare an analysis sample Product: The tissue was stored in a stock solution (Stock solution: 0.1M HClO4, 0.1 mM EDTA, 0.1 mM Na2S2O5). After homogenization, the supernatant was centrifuged (13000 rpm, 10 min), and the neurotransmitter dopamine in the striatum was analyzed by electrochemical analysis. Variety. Next, dopamine (DA) was separately analyzed and the standard line was purchased from Sigma Aldrich. The analysis conditions were as follows. The column was Suhshell C18, 100×4.6 mm, 2.6 μm; mobile phase (1 L, pH 3.74): 0.74 mM sodium-1-Octanesulfaoate (SOS), 100 mM. Phosphate sodium salt, 0.027 mM EDTA 2M potassium chloride and 60 mL methanol; detector: Decade II, using a glassy carbon electrode for a digital electrochemical amperometric detector with an applied potential of 650 mV vs. Ag/AgCl Flow rate: 500 μL/min; range: 5 nA; injection volume: 15 μL.

(肝臟組織之生物活性指標測定) (Measurement of biological activity index of liver tissue)

關於肝臟氧化修飾後蛋白羰基含量測定,肝組織樣本配置:解剖200-300毫克的組織。用磷酸鹽緩衝鹽溶液沖洗組織,去除任何紅細胞或凝塊,含有顯著量的血紅素,特別是血紅蛋白將干擾測定。將組織在1-2ml冷緩衝液(即50mM MES或磷酸鹽,pH7.0)中勻漿化。在4℃下10,000×g離心15分鐘。取出上清液並儲存在冰上,如果不是同一天測定,在-80℃冷凍,樣品將穩定至少一個月。檢查在280nm和260nm處的上清吸光度以確定是否存在污染樣品中存在的核酸。使用均質化緩衝液一個空白。如果比率280/260小於1,進一步除去核酸的步驟需要1%鏈黴素硫酸鹽(streptomycin sulfate)。 For the determination of protein carbonyl content after hepatic oxidation modification, liver tissue sample configuration: dissect 200-300 mg of tissue. Rinse the tissue with phosphate buffered saline to remove any red blood cells or clots that contain significant amounts of hemoglobin, especially hemoglobin, which will interfere with the assay. The tissue was homogenized in 1-2 ml of cold buffer (i.e., 50 mM MES or phosphate, pH 7.0). Centrifuge at 10,000 xg for 15 minutes at 4 °C. The supernatant was removed and stored on ice. If not measured on the same day, frozen at -80 ° C, the sample will be stable for at least one month. The supernatant absorbance at 280 nm and 260 nm was examined to determine if there was a nucleic acid present in the contaminated sample. Use a homogenization buffer for a blank. If the ratio 280/260 is less than 1, the step of further removing the nucleic acid requires 1% streptomycin sulfate.

關於肝臟脂質氧化丙二醛TBARS含量測定,肝組織樣本配置:稱量約25mg組織到1.5ml離心管中。加入250μl含有蛋白酶的RIPA緩衝液選擇抑製劑。在40V在冰上超音波處理15秒。在4℃下以1,600×g離心管10分鐘。使用上清液分析。將上清液儲存在冰上。如果不是同一天測定,在-80℃冷凍,樣品將穩定一個月,組織勻漿在測定前不需要稀釋。 For determination of liver lipid oxidized malondialdehyde TBARS content, liver tissue sample configuration: Weigh approximately 25 mg of tissue into a 1.5 ml centrifuge tube. 250 μl of protease-containing RIPA buffer selection inhibitor was added. Ultrasonic processing on ice for 15 seconds at 40V. The tube was centrifuged at 1,600 x g for 10 minutes at 4 °C. Use the supernatant for analysis. Store the supernatant on ice. If not measured on the same day, the sample will be stable for one month after freezing at -80 ° C. The tissue homogenate does not need to be diluted before the assay.

關於肝臟8-oxodG含量測定,肝組織樣本配置:稱量約25mg組織到1.5ml離心管中。加入1000μl蔗糖溶液緩衝,如果不是同一天測定,在-80℃冷凍,樣品將穩定一個月。 For liver 8-oxodG content determination, liver tissue sample configuration: Weigh approximately 25 mg of tissue into a 1.5 ml centrifuge tube. Add 1000 μl sucrose solution buffer, if not measured on the same day, freeze at -80 ° C, the sample will be stable for one month.

(抗氧化生化指標測定) (Measurement of antioxidant biochemical indicators)

關於血液超氧歧化酵素質活性測定(Superoxide dismutase,SOD),血液樣品配置:使用抗凝血劑例如肝素,檸檬酸鹽或EDTA收集血液。在4℃下,在1,000×g下離心血液10分鐘,移除頂部黃色層與白色層,取出白色的血沉棕黃層(白細胞)並丟棄。RBC紅細胞在4倍體積的冰冷的水中裂解。在4℃下以10,000×g離心15分鐘,收集上清液(紅細胞裂解物)用於測定並在冰上儲存。如果沒有在同一天並在-80℃下冷凍,樣品將穩定至少一次月。在測定前用樣品緩衝液將紅細胞裂解物以1:10-1:20稀釋。 Regarding blood superoxide dismutase (SOD), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

關於血液葡萄糖六磷酸去氫酵素活性測定(Glucose-6-phosphate dehydrogenase,G6PDH),血液樣品配置:使用抗凝血劑如肝素或EDTA收集血液。在4℃下以1,000×g離心10分鐘。取出頂部的血漿和血沉棕黃層。用磷酸鹽緩衝鹽水(pH 7.4)稀釋紅細胞1:1,並放置冰(即1ml紅細胞和1ml緩衝液)。在冰上,用少量短脈沖超聲處理紅細胞以打破細胞。如果不是同一天測定,在-80℃冷凍。樣品將穩定一個月同時儲存在-80℃。在測定前用測定緩衝液進一步稀釋裂解物1:10-1:20。 Regarding blood glucose hexaphosphate dehydrogenase (G6PDH), blood sample configuration: blood is collected using an anticoagulant such as heparin or EDTA. It was centrifuged at 1,000 x g for 10 minutes at 4 °C. Remove the top plasma and buffy coat. Red blood cells were diluted 1:1 with phosphate buffered saline (pH 7.4) and placed in ice (i.e., 1 ml of red blood cells and 1 ml of buffer). On ice, red blood cells were sonicated with a small amount of short pulses to break the cells. If not measured on the same day, freeze at -80 °C. The sample will be stable for one month and stored at -80 °C. The lysate was further diluted 1:10:20 with assay buffer prior to assay.

關於血液過氧化氫酵素活性測定(Catalase),血液樣品配置:使用抗凝血劑例如肝素,檸檬酸鹽或EDTA收集血液。在4℃下,在1,000×g下離心血液10分鐘,移除頂部黃色層與白色層,取出白色的血沉棕黃層(白細胞)並丟棄。RBC紅細胞在4倍體積的冰冷的水中裂解。在4℃下以10,000×g離心15分鐘,收集上清液(紅細胞裂解物)用於測定並在冰上儲存。如果沒有在同一天並在-80℃下冷 凍,樣品將穩定至少一次月。在測定前用樣品緩衝液將紅細胞裂解物以1:10-1:20稀釋。 For blood catalase activity assay (Catalase), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not on the same day and at -80 ° C cold After freezing, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

關於血液麩胱甘肽過氧化酵素活性測定(Glutathione peroxidase,GPx),血液樣品配置:使用抗凝血劑例如肝素,檸檬酸鹽或EDTA收集血液。在4℃下,在1,000×g下離心血液10分鐘,移除頂部黃色層與白色層,取出白色的血沉棕黃層(白細胞)並丟棄。RBC紅細胞在4倍體積的冰冷的水中裂解。在4℃下以10,000×g離心15分鐘,收集上清液(紅細胞裂解物)用於測定並在冰上儲存。如果沒有在同一天並在-80℃下冷凍,樣品將穩定至少一次月。在測定前用樣品緩衝液將紅細胞裂解物以1:10-1:20稀釋。 Regarding blood glutathione peroxidase (GPx), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

關於血液麩胱甘肽還原酵素活性測定(Glutathione reductase,GRd),血液樣品配置:使用抗凝血劑例如肝素,檸檬酸鹽或EDTA收集血液。在4℃下,在1,000×g下離心血液10分鐘,移除頂部黃色層與白色層,取出白色的血沉棕黃層(白細胞)並丟棄。RBC紅細胞在4倍體積的冰冷的水中裂解。在4℃下以10,000×g離心15分鐘,收集上清液(紅細胞裂解物)用於測定並在冰上儲存。如果沒有在同一天並在-80℃下冷凍,樣品將穩定至少一次月。在測定前用樣品緩衝液將紅細胞裂解物以1:10-1:20稀釋。 Regarding blood glutathione reductase (GRd), blood sample configuration: blood is collected using an anticoagulant such as heparin, citrate or EDTA. The blood was centrifuged at 1,000 x g for 10 minutes at 4 ° C, the top yellow layer and the white layer were removed, and the white buffy coat (white blood cells) was taken out and discarded. RBC red blood cells were lysed in 4 volumes of ice-cold water. After centrifugation at 10,000 x g for 15 minutes at 4 ° C, the supernatant (erythrocyte lysate) was collected for measurement and stored on ice. If not frozen on the same day and at -80 ° C, the sample will be stable for at least one month. Red blood cell lysates were diluted 1:10:20 with sample buffer prior to assay.

腦部組織老化之生物活性指標測定的結果如下,比較五組給藥組與疾病組的小鼠紋狀體後,發現口服給予猴頭菇萃取物JMH001粉末1g/kg,DA有上升(P<0.001),顯示有效改善紋狀體組織內神經傳遞物質多巴胺含量。給藥組紋狀體神經傳遞物質含量分析(圖1和表1)。 The results of the bioactivity indicators of brain tissue aging were as follows. After comparing the striatum of the mice in the five groups and the disease group, it was found that the oral administration of the extract of JMH001 powder 1g/kg, DA increased (P< 0.001), shown to effectively improve the dopamine content of neurotransmitters in the striatum. The striatum neurotransmitter content of the drug-administered group was analyzed (Fig. 1 and Table 1).

肝臟組織之生物活性指標測定的結果如下,比較五組給藥組與疾病組後,發現口服給予JWH001粉末1g/kg,MP 1g/kg,脂質過氧化物丙二醛(MDA)有下降(P<0.05)。此實驗結果顯示JWH001或MP口服1g/kg時,能有效改善肝臟氧化狀況。實驗結果顯示JWH001 1g/kg,1g/kg組的MDA有下降甚至比健康組低,統計有顯著差異。(圖2和表2)。比較五組給藥組與疾病組後,發現口服給予JWH001粉末1g/kg,MP 1g/kg和RP 1g/kg,羰基含量有下降(P<0.001)。此實驗結果顯示JWH001粉末,MP,RP口服1g/kg時,能有效改善肝臟脂質氧化狀況。實驗結果顯示於圖3和表3。比較五組給藥組與疾病組後,發現口服給予JWH001粉末1g/kg,MP 1g/kg和RP 1g/kg,8-oxodG無顯著性差異(P>0.05)。此實驗結果顯示JWH001粉末,MP,RP口服1g/kg時,能有效改善肝臟脂質氧化狀況。實驗結果顯示於圖4和表4。 The results of the bioactivity index of liver tissue were as follows. After comparing the five groups of the drug group and the disease group, it was found that the JWH001 powder was orally administered at 1 g/kg, MP 1 g/kg, and the lipid peroxide malondialdehyde (MDA) was decreased (P <0.05). The results of this experiment show that JWH001 or MP can effectively improve liver oxidation when taken orally at 1g/kg. The experimental results showed that the MDA of JWH001 1g/kg and 1g/kg group was even lower than that of the healthy group, and the statistics were significantly different. (Figure 2 and Table 2). After comparing the five groups of the drug-administered group and the disease group, it was found that the JWH001 powder was orally administered at 1 g/kg, MP 1 g/kg and RP 1 g/kg, and the carbonyl content was decreased (P < 0.001). The results of this experiment show that JWH001 powder, MP, RP oral 1g / kg, can effectively improve liver lipid oxidation. The experimental results are shown in Figure 3 and Table 3. After comparing the five groups of the drug-administered group and the disease group, it was found that there was no significant difference between the oral administration of JWH001 powder 1g/kg, MP 1g/kg and RP 1g/kg, and 8-oxodG (P>0.05). The results of this experiment show that JWH001 powder, MP, RP oral 1g / kg, can effectively improve liver lipid oxidation. The experimental results are shown in Figure 4 and Table 4.

抗氧化生化指標測定的結果如下,比較五組給藥組與疾病組後,發現口服給予JWH001 1g/kg組的G6PDH、GRd、GPx有上升(P<0.05),但SOD和Catalase實驗結果統計無顯著差異。(圖5至9和表5)。 The results of antioxidative biochemical indicators were as follows. After comparing the five groups of the drug group and the disease group, it was found that the G6PDH, GRd, and GPx in the JWH001 1g/kg group increased (P<0.05), but the results of SOD and Catalase experiments were not statistical. Significant difference. (Figures 5 to 9 and Table 5).

與MPTP+H2O組比較,"*" P<0.05,"**" P<0.01,"***" P<0.001 Compared with the MPTP+H2O group, "*" P<0.05, "**" P<0.01, "***" P<0.001

超微粉碎技術是近年來迅速發展的一項新技術。例如,中藥材中的有效成分大多分佈在細胞內,常規飲片煎煮時只能使部分有效成分釋放出來,有效成分利用率10-30%,而採用超微粉碎技術,如將中藥飲片粉碎至300目左右,細胞 破壁率將達到86.7%,提高了藥材中有效成分的溶出,大大增強其藥效,有效成分利用率在90%以上,達到減少藥材使用量及保護藥材資源,同時還可提高藥品的品質增加藥效。本創作使用超微粉碎技術,將猴頭菇粉末110壓碎至直徑10微米至12微米,經過實驗證明直徑10微米至12微米的猴頭菇粉末110將可有效提高成分利用率。同時使用膠狀物質層120與食用殼層130包覆猴頭菇粉末110,避免胃酸與膽汁的影響,通過胃而到腸道,有利於人體吸收。 Superfine pulverization technology is a new technology that has developed rapidly in recent years. For example, most of the active ingredients in Chinese herbal medicines are distributed in cells. When the conventional decoction pieces are boiled, only some of the active ingredients can be released. The utilization rate of the active ingredients is 10-30%, and the ultrafine grinding technology is used, such as crushing the Chinese medicine pieces to About 300 mesh, cells The breaking rate will reach 86.7%, which will improve the dissolution of the active ingredients in the medicinal materials, greatly enhance its efficacy, and the utilization rate of active ingredients will be above 90%, which will reduce the use of medicinal materials and protect the resources of medicinal materials, and at the same time increase the quality of medicines. Drug effect. This creation uses the ultrafine pulverization technique to crush the Hericium erinaceus powder 110 to a diameter of 10 micrometers to 12 micrometers. It has been experimentally proven that the larvae powder 110 having a diameter of 10 micrometers to 12 micrometers can effectively improve the utilization ratio of the components. At the same time, the gelatinous substance layer 120 and the edible shell layer 130 are used to coat the Hericium erinaceus powder 110 to avoid the influence of gastric acid and bile, and pass through the stomach to the intestinal tract, which is beneficial to the human body to absorb.

以上所述僅為本創作之較佳實施例,非用以限定本創作之專利範圍,其他運用本創作之專利精神之等效變化,均應俱屬本創作之專利範圍。 The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the scope of the patents of the present invention. Other equivalent variations of the patent spirit using the present invention are all within the scope of the patent.

Claims (6)

一種包覆猴頭菇粉末的包埋顆粒,包括:多個猴頭菇粉末,其直徑範圍為10微米至12微米;一膠狀物質層,該膠狀物質層是包覆該猴頭菇粉末;及一食用殼層,是包覆該膠狀物質層。 An embedded granule coated with a powder of Hericium erinaceus, comprising: a plurality of Hericium erinaceus powders having a diameter ranging from 10 micrometers to 12 micrometers; a gelatinous substance layer coating the powder of the Hericium erinaceus And an edible shell layer covering the gelatinous substance layer. 如申請專利範圍第1項所述之包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠紋狀體組織內神經傳遞物質多巴胺含量為226.80±66.03ng/g。 The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the dopamine content of the neurotransmitter in the striatum of the mouse was 226.80±66.03 ng/g. . 如申請專利範圍第1項所述之包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠肝臟的脂質過氧化物丙二醛含量為772.86±225.23μM。 The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the lipid peroxide malondialdehyde content of the mouse liver was 772.86±225.23 μM. 如申請專利範圍第1項所述之包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠肝臟的羰基含量為385.05±235.15nmol/mg。 The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the carbonyl content of the mouse liver was 385.05±235.15 nmol/mg. 如申請專利範圍第1項所述之包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠8-oxodG含量為0.73±0.18ng/mL。 The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, and the mouse 8-oxodG content was 0.73±0.18 ng/mL. 如申請專利範圍第1項所述之包覆猴頭菇粉末的包埋顆粒,其中,該猴頭菇粉末以1g/kg口服一天一次,總計30天,施加於已腹腔內注射1-甲基-4-苯基-1,2,3,6-四氫吡啶20mg/kg一天一次,總計5天的小鼠,得到小鼠血液中的超氧化物歧化酵素含量為89.68±2.71U/ml。 The embedded granule of the coated Hericium erinaceus powder according to claim 1, wherein the Hericium erinaceus powder is orally administered once a day for 1 day at a rate of 1 g/kg, and is applied to the intraperitoneal injection of 1-methyl -4-Phenyl-1,2,3,6-tetrahydropyridine 20 mg/kg once a day for 5 days in total, the superoxide dismutase content in the blood of the mice was 89.68±2.71 U/ml.
TW107202552U 2018-02-23 2018-02-23 Encapsulated particle coated with lion's mane mushroom powder TWM568137U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW107202552U TWM568137U (en) 2018-02-23 2018-02-23 Encapsulated particle coated with lion's mane mushroom powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW107202552U TWM568137U (en) 2018-02-23 2018-02-23 Encapsulated particle coated with lion's mane mushroom powder

Publications (1)

Publication Number Publication Date
TWM568137U true TWM568137U (en) 2018-10-11

Family

ID=64871255

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107202552U TWM568137U (en) 2018-02-23 2018-02-23 Encapsulated particle coated with lion's mane mushroom powder

Country Status (1)

Country Link
TW (1) TWM568137U (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112741305A (en) * 2020-12-30 2021-05-04 李长青 Hericium erinaceus product and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112741305A (en) * 2020-12-30 2021-05-04 李长青 Hericium erinaceus product and preparation method thereof

Similar Documents

Publication Publication Date Title
Upton Stinging nettles leaf (Urtica dioica L.): Extraordinary vegetable medicine
Mukherjee et al. Comparison of the protective effects of steamed and cooked broccolis on ischaemia–reperfusion-induced cardiac injury
KR20140126087A (en) Beverages that always immune function and antioxidant substances
Jayasuriya et al. Anti‐inflammatory activity of Pleurotus ostreatus, a culinary medicinal mushroom, in Wistar rats
CN104274509B (en) Healthy product composition containing cordyceps sinensis and eucommia Bark male flower and its preparation method and application
TWM568137U (en) Encapsulated particle coated with lion&#39;s mane mushroom powder
Ojieh et al. Hypoglycemic and hypolipidaemic effect of allium cepa in streptozotocin-induced diabetes
Okechukwu et al. The Effect of ethanol leaf extract of Jatropha curcas on chloroform induced hepatotoxicity in Albino rats
KR101160088B1 (en) Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover
CN110801456A (en) Application of cordycepin in preparation of liver protection product
KR20200081553A (en) Composition for the prevention and improvement of Antitussive and Expectorant
CN113559152B (en) Liver-protecting traditional Chinese medicine composition and beverage as well as preparation method and application thereof
TW201842925A (en) Hericium powder for delaying functional degeneration of the brain and method thereof
CN114947129A (en) Uric acid-reducing cichorium grandiflorum and angelica dahurica health food and preparation method thereof
Jinyuan Effects of curcumin on physical fatigue and oxidative damage in forced swimming mice
KR101318330B1 (en) Pharmaceutical composition and functional food having anti-depressant activity, and preparation method of the same
WO2021251920A1 (en) Use of propolis obtained by special extraction method in liquid mixtures
CN104922277A (en) Application of fructus schizandrae extract in medicine for rescuing paraquat poisoning
CN101869695B (en) Medicinal composition for improving immunity and application thereof
CN110840950A (en) Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury
CN103705547A (en) Mythic Fungus spore wall breaking treatment agent
Khan et al. Cardamom Safety
AU2021105462A4 (en) Use of fructus corni nano-powder in resisting type 2 diabetes mellitus
CN107252444A (en) It is a kind of to be used to treat and/or prevent herbal composite of prostatic disorders and its preparation method and application
Singh et al. Chemopreventive and antioxidative effects of Averrhoa carambola (star fruit) extract against diethylnitrosamine induced hepatocarcinogenesis